<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2565-005X</journal-id>
<journal-title><![CDATA[Gaceta mexicana de oncología]]></journal-title>
<abbrev-journal-title><![CDATA[Gac. mex. oncol.]]></abbrev-journal-title>
<issn>2565-005X</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Oncología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2565-005X2024000100030</article-id>
<article-id pub-id-type="doi">10.24875/j.gamo.m24000261</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Consenso mexicano de cáncer mamario. Manejo del cáncer de mama temprano]]></article-title>
<article-title xml:lang="en"><![CDATA[Mexican breast cancer consensus. Management of early breast cancer]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bargalló-Rocha]]></surname>
<given-names><![CDATA[Juan E.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aguilar-Villanueva]]></surname>
<given-names><![CDATA[Sergio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ahumada-Pámanes]]></surname>
<given-names><![CDATA[Carolina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arce-Salinas]]></surname>
<given-names><![CDATA[Claudia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Álvarez-Cano]]></surname>
<given-names><![CDATA[Alethia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Baley-Spindel]]></surname>
<given-names><![CDATA[Isaac]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bautista-Piña]]></surname>
<given-names><![CDATA[Verónica]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cervantes-Sánchez]]></surname>
<given-names><![CDATA[Guadalupe]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chávez-MacGregor]]></surname>
<given-names><![CDATA[Mariana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Esparza-Arias]]></surname>
<given-names><![CDATA[Nereida]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Figueroa-Padilla]]></surname>
<given-names><![CDATA[Jonathán]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Flores-Balcázar]]></surname>
<given-names><![CDATA[Christian H.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Flores-Moreno]]></surname>
<given-names><![CDATA[Sonia Ma.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Maffuz-Aziz]]></surname>
<given-names><![CDATA[Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Maldonado-Magos]]></surname>
<given-names><![CDATA[Federico]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lara-Tamburrino]]></surname>
<given-names><![CDATA[Ma. del Carmen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lluch-Hernández]]></surname>
<given-names><![CDATA[Ana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Navarro-Santiesteban]]></surname>
<given-names><![CDATA[Sarina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez-Sánchez]]></surname>
<given-names><![CDATA[Víctor M.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Poitevín-Chacón]]></surname>
<given-names><![CDATA[Adela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ruvalcaba-Limón]]></surname>
<given-names><![CDATA[Eva]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Salas-González]]></surname>
<given-names><![CDATA[Efraín]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sarricolea-Puch]]></surname>
<given-names><![CDATA[Amelia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Soto-Pérez-de-Celis]]></surname>
<given-names><![CDATA[Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Torrecillas-Torres]]></surname>
<given-names><![CDATA[Laura]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Valero-Castillo]]></surname>
<given-names><![CDATA[Vicente]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Villaseñor-Navarro]]></surname>
<given-names><![CDATA[Yolanda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chávarri-Guerra]]></surname>
<given-names><![CDATA[Yanin]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cárdenas-Sánchez]]></surname>
<given-names><![CDATA[Jesús]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Cancerología, Secretaría de Salud Departamento de Tumores Mamarios ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Universitario Dr. José Eleuterio González Radiooncología ]]></institution>
<addr-line><![CDATA[Monterrey, N.L ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Centro Médico ABC Cirugía Plástica ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Instituto de Enfermedades de la Mama Servicio de Patología ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado Centro Médico Nacional 20 de Noviembre Oncología Médica]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,The University of Texas Departamento de Investigación de Servicios de Salud ]]></institution>
<addr-line><![CDATA[Houston Texas]]></addr-line>
<country>EE.UU</country>
</aff>
<aff id="Af7">
<institution><![CDATA[,Secretaría de Salud Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Oncología Médica]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="Af8">
<institution><![CDATA[,Hospital Regional de Alta Especialidad Materno-Infantil Cirugía Oncológica ]]></institution>
<addr-line><![CDATA[Monterrey, N.L ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af9">
<institution><![CDATA[,Grupo CT Scanner de México  ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="A10">
<institution><![CDATA[,Hospital Clínico Oncología Médica ]]></institution>
<addr-line><![CDATA[Valencia ]]></addr-line>
<country>España</country>
</aff>
<aff id="A11">
<institution><![CDATA[,Hospital General Agustín O'Horan Cirugía Oncológica ]]></institution>
<addr-line><![CDATA[Mérida, Yuc ]]></addr-line>
<country>México</country>
</aff>
<aff id="A12">
<institution><![CDATA[,Médica Sur Departamento de Radioterapia ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="A13">
<institution><![CDATA[,El Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado Centro Médico de Occidente Departamento de Oncología]]></institution>
<addr-line><![CDATA[Guadalajara Jal]]></addr-line>
<country>México</country>
</aff>
<aff id="A14">
<institution><![CDATA[,Unidad Médica de Alta Especialidad Ignacio García Téllez Radioterapia ]]></institution>
<addr-line><![CDATA[Mérida Yuc]]></addr-line>
<country>México</country>
</aff>
<aff id="A15">
<institution><![CDATA[,Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Departamento de Hemato-Oncología ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="A16">
<institution><![CDATA[,Centro Médico de Colima Oncología Médica ]]></institution>
<addr-line><![CDATA[Col ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2024</year>
</pub-date>
<volume>23</volume>
<numero>1</numero>
<fpage>30</fpage>
<lpage>61</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2565-005X2024000100030&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2565-005X2024000100030&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2565-005X2024000100030&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El cáncer mamario en estadios tempranos tiene un manejo local (quirúrgico y radioterapia) y sistémico específico. Este tipo de cáncer incluye el carcinoma ductal in situ y los cánceres de mama en estadios I, IIA, IIB y IIIA. Esta décima actualización del Consenso Mexicano de Cáncer Mamario abordó el manejo de los estadios tempranos. La difusión de este consenso contribuye a la actualización y homogeneidad de criterios de manejo del cáncer mamario y el objetivo de este artículo es presentar la actualización en el manejo multidisciplinario del cáncer de mama.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Breast cancer, in early stages, has specific surgical, radiotherapy, and systemic management. This type of cancer includes ductal carcinoma in situ and breast cancers in stages I, IIA, IIB, and IIIA. This tenth update of the Mexican Breast Cancer Consensus addressed the management of early stages. The dissemination of this consensus contributes to the updating and homogeneity of breast cancer management criteria. This article aims to present the update in the multidisciplinary management of breast cancer.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Cáncer de mama]]></kwd>
<kwd lng="es"><![CDATA[Estadios tempranos]]></kwd>
<kwd lng="es"><![CDATA[Consenso]]></kwd>
<kwd lng="en"><![CDATA[Breast cancer]]></kwd>
<kwd lng="en"><![CDATA[Early stage]]></kwd>
<kwd lng="en"><![CDATA[Consensus]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Temple-Oberle]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Shea-Budgell]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Semple]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Schrag]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Barreto]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consensus review of optimal perioperative care in breast reconstruction:Enhanced Recovery after Surgery (ERAS) Society Recommendations]]></article-title>
<source><![CDATA[Plast Reconstr Surg]]></source>
<year>2017</year>
<volume>139</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1056e-71e</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chiu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Aleshi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Esserman]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Inglis-Arkell]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Yap]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Whitlock]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improved analgesia and reduced post-operative nausea and vomiting after implementation of an enhanced recovery after surgery (ERAS) pathway for total mastectomy]]></article-title>
<source><![CDATA[BMC Anesthesiol]]></source>
<year>2018</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>41</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lemoine]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Joshi]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
<name>
<surname><![CDATA[Van de Velde]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bonnet]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PROSPECT Working Group collaborators. PROSPECT guideline for oncological breast surgery:a systematic review and procedure-specific postoperative pain management recommendations]]></article-title>
<source><![CDATA[Anaesthesia]]></source>
<year>2020</year>
<volume>75</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>664-73</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bashandy]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Abbas]]></surname>
<given-names><![CDATA[DN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pectoral nerves I and II blocks in multimodal analgesia for breast cancer surgery:a randomized clinical trial]]></article-title>
<source><![CDATA[Reg Anesth Pain Med]]></source>
<year>2015</year>
<volume>40</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>68-74</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Versyck]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[van Geffen]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Chin]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analgesic efficacy of the Pecs II block:a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Anaesthesia]]></source>
<year>2019</year>
<volume>74</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>663-73</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fajardo Pérez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[García Miguel]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[López Álvarez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Diéguez García]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Alfaro de la Torre]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bloqueo de las ramas laterales y anteriores de los nervios intercostales para analgesia de mama]]></article-title>
<source><![CDATA[Cir May Amb]]></source>
<year>2012</year>
<volume>17</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>95-104</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fajardo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Alfaro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serratus-intercostal plane block. An encouraging approach for breast surgery]]></article-title>
<source><![CDATA[J Assoc Anesth AAGBI]]></source>
<year>2013</year>
<volume>2</volume>
<page-range>1-3</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diéguez García]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Fajardo Pérez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[López Álvarez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Alfaro de la Torre]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Pensado Castiñeiras]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abordaje guiado por ultrasonidos de los nervios intercostales en la línea media axilar para cirugía de mama no reconstructiva y de la axila]]></article-title>
<source><![CDATA[Rev Esp Anestesiol Reanim]]></source>
<year>2013</year>
<volume>60</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>365-70</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diéguez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Fajardo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Alfaro]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[BRILMA methylene blue in cadavers. Anatomical dissection]]></article-title>
<source><![CDATA[Rev Esp Anestesiol Reanim]]></source>
<year>2016</year>
<volume>63</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>307-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Syal]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Chandel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of the post-operative analgesic effect of paravertebral block, pectoral nerve block and local infiltration in patients undergoing modified radical mastectomy:A randomised double-blind trial]]></article-title>
<source><![CDATA[Indian J Anaesth]]></source>
<year>2017</year>
<volume>61</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>643-8</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de la Torre]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Will the new thoracic fascial blocks be as effective as paravertebral block?]]></article-title>
<source><![CDATA[Rev Esp Anestesiol Reanim]]></source>
<year>2016</year>
<volume>63</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>553-5</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diéguez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Casasa]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fajardo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bloqueos guiados por ultrasonidos para cirugía mamaria]]></article-title>
<source><![CDATA[Rev Esp Anestesiol Reanim]]></source>
<year>2016</year>
<volume>63</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>159-67</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Veronesi]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1981</year>
<volume>2</volume>
<numero>305(1)</numero>
<issue>305(1)</issue>
<page-range>6-11</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Veronesi]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Conservative treatment of early breast cancer. Long-term results of 1232 cases treated with quadrantectomy, axillary dissection, and radiotherapy]]></article-title>
<source><![CDATA[Ann Surg]]></source>
<year>1990</year>
<volume>211</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>250-9</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Collins]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Darby]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Elphinstone]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:an overview of the randomized trials]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2005</year>
<volume>366</volume>
<numero>9503</numero>
<issue>9503</issue>
<page-range>2087-106</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wapnir]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Dignam]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mamounas]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
<name>
<surname><![CDATA[Jeong]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2009</year>
<volume>27</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>2466-73</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Houssami]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Macaskill]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Marinovich]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Dixon]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Irwig]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Brennan]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy]]></article-title>
<source><![CDATA[Eur J Cancer]]></source>
<year>2010</year>
<volume>46</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>3219-32</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Almeida]]></surname>
<given-names><![CDATA[NR]]></given-names>
</name>
<name>
<surname><![CDATA[Brenelli]]></surname>
<given-names><![CDATA[FP]]></given-names>
</name>
<name>
<surname><![CDATA[Dos Santos]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Torresan]]></surname>
<given-names><![CDATA[RZ]]></given-names>
</name>
<name>
<surname><![CDATA[Shinzato]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Cardoso-Filho]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative study of surgical and oncological outcomes in oncoplastic versus non oncoplastic breast-conserving surgery for breast cancer treatment]]></article-title>
<source><![CDATA[JPRAS Open]]></source>
<year>2021</year>
<volume>29</volume>
<page-range>184-94</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cuttino]]></surname>
<given-names><![CDATA[LW]]></given-names>
</name>
<name>
<surname><![CDATA[McCall]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kubicky]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ballman]]></surname>
<given-names><![CDATA[KV]]></given-names>
</name>
<name>
<surname><![CDATA[Le-Petross]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hunt]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Feasibility of radiation therapy after breast-conserving surgery for multiple ipsilateral breast cancer:An initial report from ACOSOG Z11102 (Alliance) Trial]]></article-title>
<source><![CDATA[Int J Radiat Oncol Biol Phys]]></source>
<year>2022</year>
<volume>112</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>636-42</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruvalcaba Limón]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Espejo Fonseca]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bautista]]></surname>
<given-names><![CDATA[Piña]]></given-names>
</name>
<name>
<surname><![CDATA[Madero Preciado]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Capurso García]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Serratos Garduño]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Control radiológico intraoperatorio de una pieza quirúrgica en lesiones mamarias no palpables]]></article-title>
<source><![CDATA[Ginecol Obstet Mex]]></source>
<year>2009</year>
<volume>77</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>407-18</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moran]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Schnitt]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Giuliano]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Horton]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Society of Surgical Oncology;American Society for Radiation Oncology. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer]]></article-title>
<source><![CDATA[Int J Radiat Oncol Biol Phys]]></source>
<year>2014</year>
<volume>88</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>553-64</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heeg]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Hölmich]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
<name>
<surname><![CDATA[Bodilsen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tollenaar]]></surname>
<given-names><![CDATA[RAEM]]></given-names>
</name>
<name>
<surname><![CDATA[Laenkholm]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rates of re-excision and conversion to mastectomy after breast-conserving surgery with or without oncoplastic surgery:a nationwide population-based study]]></article-title>
<source><![CDATA[Br J Surg]]></source>
<year>2020</year>
<volume>107</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>1762-72</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sherwell-Cabello]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Maffuz-Aziz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Villegas-Carlos]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez-Reyes]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Labastida-Almendaro]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Cuevas]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factibilidad y resultado estético de la cirugía oncoplasica en el tratamiento de cáncer de mama]]></article-title>
<source><![CDATA[Cir Cir]]></source>
<year>2015</year>
<volume>83</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>199-205</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Halsted]]></surname>
<given-names><![CDATA[WS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June, 1889, to January, 1894]]></article-title>
<source><![CDATA[Ann Surg]]></source>
<year>1894</year>
<volume>20</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>497-555</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Montague]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Redmond]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Deutsch]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[Zauber]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Findings from NSABP Protocol No. B-04-comparison of radical mastectomy with alternative treatments for primary breast cancer. I. Radiation compliance and its relation to treatment outcome]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>1980</year>
<volume>46</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-13</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chiesa]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Sacchini]]></surname>
<given-names><![CDATA[VS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk-reducing mastectomy]]></article-title>
<source><![CDATA[Minerva Ginecol]]></source>
<year>2016</year>
<volume>68</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>544-7</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gonzalez]]></surname>
<given-names><![CDATA[EG]]></given-names>
</name>
<name>
<surname><![CDATA[Rancati]]></surname>
<given-names><![CDATA[AO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Skin-sparing mastectomy]]></article-title>
<source><![CDATA[Gland Surg]]></source>
<year>2015</year>
<volume>4</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>541-53</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosenkranz]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Ballman]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[McCall]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[McCarthy]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kubicky]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Cuttino]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cosmetic outcomes following breast-conservation surgery and radiation for multiple ipsilateral breast cancer:Data from the alliance Z11102 study]]></article-title>
<source><![CDATA[Ann Surg Oncol]]></source>
<year>2020</year>
<volume>4650</volume>
<page-range>61</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de Boniface]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Szulkin]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Johansson]]></surname>
<given-names><![CDATA[ALV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Survival after breast conservation vs. mastectomy adjusted for comorbidity and socioeconomic status:A Swedish national 6-year follow-up of 48 986 women]]></article-title>
<source><![CDATA[JAMA Surg]]></source>
<year>2021</year>
<volume>156</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>628-37</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mohamedahmed]]></surname>
<given-names><![CDATA[AYY]]></given-names>
</name>
<name>
<surname><![CDATA[Zaman]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zafar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Laroiya]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Iqbal]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[MLH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of surgical and oncological outcomes between oncoplastic breast-conserving surgery versus conventional breast-conserving surgery for treatment of breast cancer:A systematic review and meta-analysis of 31 studies]]></article-title>
<source><![CDATA[Surg Oncol]]></source>
<year>2022</year>
<volume>42</volume>
<page-range>101779</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cruz-Benítez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Historia y estado actual sobre los tipos de procedimientos quirúrgicos realizados en cáncer de mama]]></article-title>
<source><![CDATA[Gac Mex Oncol]]></source>
<year>2014</year>
<volume>13</volume>
<numero>(2)</numero>
<issue>(2)</issue>
<page-range>124-33</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mariconde]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Manual de cirugía oncológica y oncoplástica de la mama]]></source>
<year>2021</year>
<edition>1.a ed</edition>
<publisher-loc><![CDATA[Córdoba, Argentina ]]></publisher-loc>
<publisher-name><![CDATA[Recfot]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Acea-Nebril]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cirugía oncoplástica conservadora en el cáncer de mama. Indicaciones y límites en su aplicación quirúrgica]]></article-title>
<source><![CDATA[Cir Esp]]></source>
<year>2005</year>
<volume>78</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>12-8</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Clough]]></surname>
<given-names><![CDATA[KB]]></given-names>
</name>
<name>
<surname><![CDATA[Cuminet]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Fitoussi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nos]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mosseri]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cosmetic sequelae after conservative treatment for breast cancer:classification and results of surgical correction]]></article-title>
<source><![CDATA[Ann Plast Surg]]></source>
<year>1998</year>
<volume>41</volume>
<page-range>471-81</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Masetti]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Di Leone]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Franceschini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Magno]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Terribile]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Fabbri]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncoplastic techniques in the conservative surgical treatment of breast cancer]]></article-title>
<source><![CDATA[Breast Cancer]]></source>
<year>2000</year>
<volume>7</volume>
<page-range>276-80</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Acea Nebril]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cirugía oncológica de la mama]]></article-title>
<source><![CDATA[Técnicas oncoplásticas y reconstructivas. Oncoplastia extrema, cirugía de precisión, puerto único]]></source>
<year>2019</year>
<edition>4.a edición</edition>
</nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<collab>Asociación Española de Cirujanos</collab>
<article-title xml:lang=""><![CDATA[Máster en cirugía de mama]]></article-title>
<source><![CDATA[Módulo 3. Cirugía conservadora oncoplástica de la mama. Asociación Española de Cirujanos]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salmon]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Paradigms for treating breast cancers have changed:The one-size-fits-all is no longer true]]></article-title>
<source><![CDATA[Arch Breast Cancer]]></source>
<year>2019</year>
<volume>6</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>144-6</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Stallard]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Doughty]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mallon]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Romics]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncological outcomes and complications after volume replacement oncoplastic breast conservations - the Glasgow experience]]></article-title>
<source><![CDATA[Breast Cancer (Auckl)]]></source>
<year>2016</year>
<volume>10</volume>
<page-range>223-8</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martellani]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Manara]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Renzi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Papa]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ramella]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Arne&#382;]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of LICAP and LTAP flaps for breast reconstruction]]></article-title>
<source><![CDATA[Acta Chir Plast]]></source>
<year>2019</year>
<volume>60</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>4-8</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hamdi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Van Landuyt]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[de Frene]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Roche]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Blondeel]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Monstrey]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The versatility of the inter-costal artery perforator (ICAP) flaps]]></article-title>
<source><![CDATA[J Plast Reconstr Aesth Surg]]></source>
<year>2006</year>
<volume>59</volume>
<page-range>644-52</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quinn]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Burrah]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[O'Ceallaigh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Highton]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Six-year experience of oncoplastic volume replacement using local perforator flaps]]></article-title>
<source><![CDATA[J Plast Reconstr Aesthet Surg]]></source>
<year>2021</year>
<volume>74</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2184-93</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Holmstrom]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Lossing]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The lateral thoracodorsal flap in breast reconstruction]]></article-title>
<source><![CDATA[Plast Reconstr Surg]]></source>
<year>1986</year>
<volume>77</volume>
<page-range>933-43</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Ryu]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[KY]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[HY]]></given-names>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Usefulness of a lateral thoracodorsal flap after breast conserving surgery in laterally located breast cancer]]></article-title>
<source><![CDATA[Arch Plast Surg]]></source>
<year>2013</year>
<volume>40</volume>
<page-range>367-73</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mangialardi]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Baldelli]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Salgarello]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Raposio]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Breast reconstruction using the lateral thoracic, thoracodorsal, and intercostal arteries perforator flaps]]></article-title>
<source><![CDATA[Plast Reconstr Surg Glob Open]]></source>
<year>2021</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O'Connell]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Yildirim]]></surname>
<given-names><![CDATA[NG]]></given-names>
</name>
<name>
<surname><![CDATA[Heeney]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[St John]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Muktar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Krupa]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The use of pedicled perforator flaps in oncoplastic breast surgery. The Royal Marsden experience. En:Official Proceedings of the 2022 Annual Meeting;Vol. XXIII]]></article-title>
<source><![CDATA[Scientific Session Abstracts]]></source>
<year>2022</year>
<page-range>1143646</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lanitis]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tekkis]]></surname>
<given-names><![CDATA[PP]]></given-names>
</name>
<name>
<surname><![CDATA[Sgourakis]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Dimopoulos]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Al Mufti]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hadjiminas]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of skin-sparing mastectomy versus non-skin-sparing mastectomy for breast cancer:a meta-analysis of observational studies]]></article-title>
<source><![CDATA[Ann Surg]]></source>
<year>2010</year>
<volume>251</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>632-9</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Su]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nipple sparing mastectomy in breast cancer patients and long-term survival outcomes:An analysis of the SEER database]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2017</year>
<volume>12</volume>
<numero>8</numero>
<issue>8</issue>
</nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Zeng]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Zou]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Yuan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognosis comparison between nipple-sparing mastectomy and total mastectomy in breast cancer:a case-control study after propensity score matching]]></article-title>
<source><![CDATA[Ann Surg Oncol]]></source>
<year>2022</year>
<volume>29</volume>
<page-range>2221-30</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weber]]></surname>
<given-names><![CDATA[WP]]></given-names>
</name>
<name>
<surname><![CDATA[Haug]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kurzeder]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bjelic-Radisic]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Koller]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Reitsamer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy]]></article-title>
<source><![CDATA[Breast Cancer Res Treat]]></source>
<year>2018</year>
<volume>172</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>523-7</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaidar-Person]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Boersma]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Poortmans]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sklair-Levy]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Offersen]]></surname>
<given-names><![CDATA[BV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Residual glandular breast tissue after mastectomy:a systematic review]]></article-title>
<source><![CDATA[Ann Surg Oncol]]></source>
<year>2020</year>
<volume>27</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>2288-96</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bromham]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Schmidt-Hansen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Astin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hasler]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Reed]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Axillary treatment for operable primary breast cancer]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2017</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>CD004561</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amin]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Edge]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
</person-group>
<source><![CDATA[AJCC cancer staging manual]]></source>
<year>2017</year>
<publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[Springer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Corso]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Galimberti]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Veronesi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[De-escalation treatment of axilla in breast cancer]]></article-title>
<source><![CDATA[Clin Transl Oncol]]></source>
<year>2020</year>
<volume>22</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>445-6</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Di Paola]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Mazzotta]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pignatelli]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Bufi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[D'Angelo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Conti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Beyond N staging in breast cancer:importance of MRI and ultrasound-based imaging]]></article-title>
<source><![CDATA[Cancers (Basel)]]></source>
<year>2022</year>
<volume>14</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>4270</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Veronesi]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Paganelli]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Viale]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Luini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zurrida]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Galimberti]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2003</year>
<volume>349</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>546-53</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krag]]></surname>
<given-names><![CDATA[DN]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Julian]]></surname>
<given-names><![CDATA[TB]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Harlow]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Costantino]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer:overall survival findings from the NSABPB-32 randomised phase 3 trial]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2010</year>
<volume>11</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>927-33</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Veronesi]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Viale]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Paganelli]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Zurrida]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Luini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Galimberti]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sentinel lymph-node biopsy in breast cancer:ten-year results of a randomized controlled study]]></article-title>
<source><![CDATA[Ann Surg]]></source>
<year>2010</year>
<volume>251</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>595-600</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galimberti]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Cole]]></surname>
<given-names><![CDATA[BF]]></given-names>
</name>
<name>
<surname><![CDATA[Zurrida]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Viale]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Luini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Veronesi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01):10-year follow-up of a randomised, controlled phase 3 trial]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2018</year>
<volume>19</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1385-93</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Solá]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Alberro]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Fraile]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Santesteban]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fabregas]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis:final results from the multicenter clinical trial AATRM 048/13/2000]]></article-title>
<source><![CDATA[Ann Surg Oncol]]></source>
<year>2023</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>120-7</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giuliano]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Ballman]]></surname>
<given-names><![CDATA[KV]]></given-names>
</name>
<name>
<surname><![CDATA[McCall]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Beitsch]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
<name>
<surname><![CDATA[Brennan]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Kelemen]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of axillary dissection vs. no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis:the ACOSOG Z0011 (Alliance) randomized clinical trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2017</year>
<volume>318</volume>
<page-range>918-26</page-range></nlm-citation>
</ref>
<ref id="B62">
<label>62</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Donker]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[van Tienhoven]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Straver]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Meijnen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[van de Velde]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mansel]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS):a randomised, multicentre, open-label, phase 3 non-inferiority trial]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2014</year>
<volume>15</volume>
<page-range>1303-10</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>63</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sávolt]]></surname>
<given-names><![CDATA[Á]]></given-names>
</name>
<name>
<surname><![CDATA[Péley]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Polgár]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Udvarhelyi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Rubovszky]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kovács]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eight-year follow up result of the OTOASOR trial:the optimal treatment of the axilla-surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer:a randomized, single centre, phase III, non-inferiority trial]]></article-title>
<source><![CDATA[Eur J Surg Oncol]]></source>
<year>2017</year>
<volume>43</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>672-9</page-range></nlm-citation>
</ref>
<ref id="B64">
<label>64</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simons]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Koppert]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
<name>
<surname><![CDATA[Luiten]]></surname>
<given-names><![CDATA[EJT]]></given-names>
</name>
<name>
<surname><![CDATA[van der Pol]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Samiei]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[de Wilt]]></surname>
<given-names><![CDATA[JHW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting:a Dutch population-based study]]></article-title>
<source><![CDATA[Breast Cancer Res Treat]]></source>
<year>2020</year>
<volume>180</volume>
<page-range>725-33</page-range></nlm-citation>
</ref>
<ref id="B65">
<label>65</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morrow]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of the node-positive axilla in breast cancer in 2017:selecting the right option]]></article-title>
<source><![CDATA[JAMA Oncol]]></source>
<year>2018</year>
<volume>4</volume>
<page-range>250-1</page-range></nlm-citation>
</ref>
<ref id="B66">
<label>66</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boughey]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Ballman]]></surname>
<given-names><![CDATA[KV]]></given-names>
</name>
<name>
<surname><![CDATA[Le-Petross]]></surname>
<given-names><![CDATA[HT]]></given-names>
</name>
<name>
<surname><![CDATA[McCall]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Mittendorf]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Ahrendt]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy:results from ACOSOG Z1071 (Alliance)]]></article-title>
<source><![CDATA[Ann Surg]]></source>
<year>2016</year>
<volume>263</volume>
<page-range>802-7</page-range></nlm-citation>
</ref>
<ref id="B67">
<label>67</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Teo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gudi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ping]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Pang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Seam]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Initial results of a novel technique of clipped node localization in breast cancer patients postneoadjuvant chemotherapy:Skin Mark clipped Axillary nodes Removal Technique (SMART trial)]]></article-title>
<source><![CDATA[Cancer Med]]></source>
<year>2020</year>
<volume>9</volume>
<page-range>1978-85</page-range></nlm-citation>
</ref>
<ref id="B68">
<label>68</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tee]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Devane]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Evoy]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Rothwell]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Geraghty]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Prichard]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer]]></article-title>
<source><![CDATA[Br J Surg]]></source>
<year>2018</year>
<volume>105</volume>
<page-range>15411552</page-range></nlm-citation>
</ref>
<ref id="B69">
<label>69</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Classe]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Loaec]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gimbergues]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Alran]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[de Lara]]></surname>
<given-names><![CDATA[CT]]></given-names>
</name>
<name>
<surname><![CDATA[Dupre]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients:the GANEA 2 study]]></article-title>
<source><![CDATA[Breast Cancer Res Treat]]></source>
<year>2018</year>
<volume>173</volume>
<page-range>343-52</page-range></nlm-citation>
</ref>
<ref id="B70">
<label>70</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kuehn]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Bauerfeind]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Fehm]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Fleige]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hausschild]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Helms]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA):a prospective, multicentre cohort study]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2013</year>
<volume>14</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>609-18</page-range></nlm-citation>
</ref>
<ref id="B71">
<label>71</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caudel]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes:implementation of targeted axillary dissection]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2016</year>
<volume>34</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1072-8</page-range></nlm-citation>
</ref>
<ref id="B72">
<label>72</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tinterri]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SINODAR-ONE Collaborative Group. Preservation of axillary lymph nodes compared with complete dissection in T1-2 breast cancer patients presenting one or two metastatic sentinel lymph nodes:The SINODAR-ONE multicenter randomized clinical trial]]></article-title>
<source><![CDATA[Ann Surg Oncol]]></source>
<year>2022</year>
<volume>29</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>5732-44</page-range></nlm-citation>
</ref>
<ref id="B73">
<label>73</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reimer]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Engel]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Offersen]]></surname>
<given-names><![CDATA[BV]]></given-names>
</name>
<name>
<surname><![CDATA[Smidt]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Gentilini]]></surname>
<given-names><![CDATA[OD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is axillary sentinel lymph node biopsy required in patients who undergo primary breast surgery?]]></article-title>
<source><![CDATA[Breast Care (Basel)]]></source>
<year>2018</year>
<volume>13</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>324-30</page-range></nlm-citation>
</ref>
<ref id="B74">
<label>74</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morigi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Peradze]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Galimberti]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Leonardi]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Radice]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Santomauro]]></surname>
<given-names><![CDATA[GI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Feasibility and surgical impact of Z0011 trial criteria in a single-Institution practice]]></article-title>
<source><![CDATA[Breast J]]></source>
<year>2020</year>
<volume>26</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1330-6</page-range></nlm-citation>
</ref>
<ref id="B75">
<label>75</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berg]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The significance of axillary node levels in the study of breast carcinoma]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>1955</year>
<volume>8</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>776-8</page-range></nlm-citation>
</ref>
<ref id="B76">
<label>76</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cirocchi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Amabile]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[De Luca]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Frusone]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Tripodi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gentile]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New classifications of axillary lymph nodes and their anatomical-clinical correlations in breast surgery]]></article-title>
<source><![CDATA[World J Surg Oncol]]></source>
<year>2021</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>93</page-range></nlm-citation>
</ref>
<ref id="B77">
<label>77</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johnston]]></surname>
<given-names><![CDATA[SRD]]></given-names>
</name>
<name>
<surname><![CDATA[Harbeck]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Hegg]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Toi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shao]]></surname>
<given-names><![CDATA[ZM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+HER2-, node-positive, high-risk, early breast cancer (monarchE)]]></article-title>
<source><![CDATA[J Clin Ocol]]></source>
<year>2020</year>
<volume>38</volume>
<numero>34</numero>
<issue>34</issue>
<page-range>3987-98</page-range></nlm-citation>
</ref>
<ref id="B78">
<label>78</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caparica]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lambertini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pondé]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Fumagalli]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[de Azambuja]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Piccart]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Post-neoadjuvant treatment and the management of residual disease in breast cancer:state of the art and perspectives]]></article-title>
<source><![CDATA[Ther Adv Med Oncol]]></source>
<year>2019</year>
<volume>11</volume>
<page-range>1758835919827714</page-range></nlm-citation>
</ref>
<ref id="B79">
<label>79</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wijaya]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical application of axillary reverse mapping in patients with breast cancer:A systematic review and meta-analysis]]></article-title>
<source><![CDATA[Breast]]></source>
<year>2020</year>
<volume>53</volume>
<page-range>189-200</page-range></nlm-citation>
</ref>
<ref id="B80">
<label>80</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boneti]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Axillary reverse mapping:mapping and preserving arm lymphatics may be important in preventing lymphedema during sentinel lymph node biopsy]]></article-title>
<source><![CDATA[J Am Coll Surg]]></source>
<year>2008</year>
<volume>206</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1038-42</page-range></nlm-citation>
</ref>
<ref id="B81">
<label>81</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pusic]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Klassen]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Snell]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cano]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[McCarthy]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Measuring and managing patient expectations for breast reconstruction:impact on quality of life and patient satisfaction]]></article-title>
<source><![CDATA[Expert Rev Pharmacoecon Outcomes Res]]></source>
<year>2012</year>
<volume>12</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>149-58</page-range></nlm-citation>
</ref>
<ref id="B82">
<label>82</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kronowitz]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kuerer]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Buchholz]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Valero]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Hunt]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A management algorithm and practical oncoplastic surgical techniques for repairing partial mastectomy defects]]></article-title>
<source><![CDATA[Plast Reconstr Surg]]></source>
<year>2008</year>
<volume>122</volume>
<page-range>1631-47</page-range></nlm-citation>
</ref>
<ref id="B83">
<label>83</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Borm]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Schönknecht]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Nestler]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Oechsner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Waschulzik]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Combs]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcomes of immediate oncoplastic surgery and adjuvant radiotherapy in breast cancer patients]]></article-title>
<source><![CDATA[BMC Cancer]]></source>
<year>2019</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>907</page-range></nlm-citation>
</ref>
<ref id="B84">
<label>84</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Losken]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hamdi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Partial breast reconstruction:Current perspectives]]></article-title>
<source><![CDATA[Plast Reconstr Surg]]></source>
<year>2009</year>
<volume>124</volume>
<page-range>722-36</page-range></nlm-citation>
</ref>
<ref id="B85">
<label>85</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spear]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Rottman]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Seiboth]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Hannan]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Breast reconstruction using a staged nipple sparing mastectomy following mastopexy or reduction]]></article-title>
<source><![CDATA[Plast Reconstr Surg]]></source>
<year>2012</year>
<volume>129</volume>
<page-range>572-81</page-range></nlm-citation>
</ref>
<ref id="B86">
<label>86</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chu]]></surname>
<given-names><![CDATA[CK]]></given-names>
</name>
<name>
<surname><![CDATA[Hanson]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Hwang]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncoplastic partial breast reconstruction:concepts and techniques]]></article-title>
<source><![CDATA[Gland Surg]]></source>
<year>2021</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>398-410</page-range></nlm-citation>
</ref>
<ref id="B87">
<label>87</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gilmour]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cutress]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gandhi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Harcourt]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Little]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Mansell]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncoplastic breast surgery:A guide to good practice]]></article-title>
<source><![CDATA[Eur J Surg Oncol]]></source>
<year>2021</year>
<volume>47</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2272-85</page-range></nlm-citation>
</ref>
<ref id="B88">
<label>88</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Losken]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Styblo]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Carlson]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
<name>
<surname><![CDATA[Amerson]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management algorithm and outcome evaluation of partial mastectomy defects treated using reduction or mastopexy techniques]]></article-title>
<source><![CDATA[Ann Plast Surg]]></source>
<year>2007</year>
<volume>59</volume>
<page-range>235-42</page-range></nlm-citation>
</ref>
<ref id="B89">
<label>89</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Akay]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Meric-Bernstam]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Hunt]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Grubbs]]></surname>
<given-names><![CDATA[EG]]></given-names>
</name>
<name>
<surname><![CDATA[Bedrosian]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Tucker]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of the MD Anderson Prognostic Index for localregional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy]]></article-title>
<source><![CDATA[Ann Surg Oncol]]></source>
<year>2012</year>
<volume>19</volume>
<page-range>901-7</page-range></nlm-citation>
</ref>
<ref id="B90">
<label>90</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khouri]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Eisenmann-Klein]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cardoso]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cooley]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
<name>
<surname><![CDATA[Kacher]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gombos]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Brava®and autologous fat transfer is a safe and effective breast augmentation alternative:Results of a 6-year, 81-patient, prospective multicenter study]]></article-title>
<source><![CDATA[Plast Reconstr Surg]]></source>
<year>2012</year>
<volume>129</volume>
<page-range>1173-87</page-range></nlm-citation>
</ref>
<ref id="B91">
<label>91</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Regan]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Casaubon]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
</person-group>
<source><![CDATA[Breast reconstruction [Internet]]]></source>
<year>2023</year>
<publisher-loc><![CDATA[Treasure Island (FL) ]]></publisher-loc>
<publisher-name><![CDATA[StatPearls Publishing;ene]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B92">
<label>92</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kronowitz]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Delayed-immediate breast reconstruction:Technical and timing considerations]]></article-title>
<source><![CDATA[Plast Reconstr Surg]]></source>
<year>2010</year>
<volume>125</volume>
<page-range>463-74</page-range></nlm-citation>
</ref>
<ref id="B93">
<label>93</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de Alcantara Filho]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Capko]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Barry]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Morrow]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pusic]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sacchini vsnipple-sparing mastectomy for breast cancer and risk-reducing surgery:The Memorial SloanKettering Cancer Center experience]]></article-title>
<source><![CDATA[Ann Surg Oncol]]></source>
<year>2011</year>
<volume>18</volume>
<page-range>311722</page-range></nlm-citation>
</ref>
<ref id="B94">
<label>94</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Acea Nebril]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[García Novoa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[García Jiménez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz Carballada]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bouzón Alejandro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Conde Iglesias]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reconstrucción mamaria inmediata mediante implante prepectoral de poliuretano. Resultados preliminares del estudio prospectivo PreQ-20]]></article-title>
<source><![CDATA[Cir Esp]]></source>
<year>2022</year>
<volume>101</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>187-97</page-range></nlm-citation>
</ref>
<ref id="B95">
<label>95</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rancati]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Direct to implant reconstruction in nipple sparing mastectomy:patient selection by preoperative digital mammogram]]></article-title>
<source><![CDATA[Plast Reconstr Surg Glob Open]]></source>
<year>2017</year>
<volume>5</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B96">
<label>96</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Urban]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prepectoral direct-to-implant breast reconstruction without placement of acellular dermal matrix or mesh after nipple-sparing mastectomy]]></article-title>
<source><![CDATA[Plast Reconstr Surg]]></source>
<year>2022</year>
<volume>150</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>973983</page-range></nlm-citation>
</ref>
<ref id="B97">
<label>97</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cordeiro]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Jazayeri]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Two-stage implant-based breast reconstruction:an evolution of the conceptual and technical approach over a two-decade period]]></article-title>
<source><![CDATA[Plast Reconstr Surg]]></source>
<year>2016</year>
<volume>138</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-11</page-range></nlm-citation>
</ref>
<ref id="B98">
<label>98</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hanson]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kapur]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Garvey]]></surname>
<given-names><![CDATA[PB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncologic safety and surveillance of autologous fat grafting following breast conservation therapy]]></article-title>
<source><![CDATA[Plast Reconstr Surg]]></source>
<year>2020</year>
<volume>146</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>215-25</page-range></nlm-citation>
</ref>
<ref id="B99">
<label>99</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and effectiveness of autologous fat grafting after breast radiotherapy:a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Plast Reconstr Surg]]></source>
<year>2021</year>
<volume>147</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B100">
<label>100</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shamoun]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Asaad]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hanson]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncologic safety of autologous fat grafting in breast reconstruction]]></article-title>
<source><![CDATA[Clin Breast Cancer]]></source>
<year>2021</year>
<volume>21</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>271-7</page-range></nlm-citation>
</ref>
<ref id="B101">
<label>101</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kronowitz]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Redesigned gluteal artery perforator flap for breast reconstruction]]></article-title>
<source><![CDATA[Plast Reconstr Surg]]></source>
<year>2008</year>
<volume>121</volume>
<page-range>728-34</page-range></nlm-citation>
</ref>
<ref id="B102">
<label>102</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parra]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Marcelli]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immediate breast reconstruction with abdominal free flap and adjuvant radiotherapy:Evaluation of quality of life and outcomes]]></article-title>
<source><![CDATA[Plast Reconstr Surg]]></source>
<year>2017</year>
<volume>140</volume>
<page-range>681</page-range></nlm-citation>
</ref>
<ref id="B103">
<label>103</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[AY]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[ZI]]></given-names>
</name>
<name>
<surname><![CDATA[Mehrara]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiotherapy in the setting of breast reconstruction:types, techniques and timing]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2017</year>
<volume>18</volume>
<page-range>e753</page-range></nlm-citation>
</ref>
<ref id="B104">
<label>104</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Jeon]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Woo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Does chemotherapy or radiotherapy affect the postoperative complication in breast cancer patients who underwent immediate breast reconstruction with tissue expander?]]></article-title>
<source><![CDATA[BMC Cancer]]></source>
<year>2021</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>88</page-range></nlm-citation>
</ref>
<ref id="B105">
<label>105</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Woo]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Paik]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Bang]]></surname>
<given-names><![CDATA[SI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The impact of expander inflation/deflation status during adjuvant radiotherapy on the complications of immediate two-stage breast reconstruction]]></article-title>
<source><![CDATA[Aesthetic Plast Surg]]></source>
<year>2017</year>
<volume>41</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>551-9</page-range></nlm-citation>
</ref>
<ref id="B106">
<label>106</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shumway]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Momoh]]></surname>
<given-names><![CDATA[AO]]></given-names>
</name>
<name>
<surname><![CDATA[Sabel]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Integration of breast reconstruction and postmastectomy radiotherapy]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2020</year>
<volume>38</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>2329-40</page-range></nlm-citation>
</ref>
<ref id="B107">
<label>107</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaidar-Person]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Vrou Offersen]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hol]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer]]></article-title>
<source><![CDATA[Radiother Oncol]]></source>
<year>2019</year>
<volume>137</volume>
<page-range>159-66</page-range></nlm-citation>
</ref>
<ref id="B108">
<label>108</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Naoum]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
<name>
<surname><![CDATA[Salama]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Niemierko]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Single stage direct-to-implant breast reconstruction has lower complication rates than tissue expander and implant and comparable rates to autologous reconstruction in patients receiving postmastectomy radiation]]></article-title>
<source><![CDATA[Int J Radiat Oncol Biol Phys]]></source>
<year>2020</year>
<volume>106</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>514-24</page-range></nlm-citation>
</ref>
<ref id="B109">
<label>109</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Daly]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Pal]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Berry]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genetic/familial high-risk assessment:Breast and ovarian, 2.2019, NCCN Clinical Practice Guidelines in Oncology]]></article-title>
<source><![CDATA[J Natl Compr Canc Netw]]></source>
<year>2021</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>77-102</page-range></nlm-citation>
</ref>
<ref id="B110">
<label>110</label><nlm-citation citation-type="">
<collab>The breast cancer risk assessment tool:online calculator (The Gail model) [Internet]</collab>
<source><![CDATA[National Cancer Institute AQ1]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B111">
<label>111</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hunt]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Euhus]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Boughey]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SSO Breast disease working group statement on prophylactic]]></article-title>
<source><![CDATA[Ann Surg Oncol]]></source>
<year>2017</year>
<volume>24</volume>
<page-range>375-97</page-range></nlm-citation>
</ref>
<ref id="B112">
<label>112</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meijers-Heijboer]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[van Geel]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[van Putten]]></surname>
<given-names><![CDATA[WL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2001</year>
<volume>345</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>159-64</page-range></nlm-citation>
</ref>
<ref id="B113">
<label>113</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lostumbo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Carbine]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
<name>
<surname><![CDATA[Wallace]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prophylactic mastectomy for the prevention of breast cancer]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2010</year>
<numero>(11)</numero>
<issue>(11)</issue>
<page-range>CD002748</page-range></nlm-citation>
</ref>
<ref id="B114">
<label>114</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramaswami]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Contralateral prophylactic mastectomy]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2017</year>
<volume>377</volume>
<page-range>13</page-range></nlm-citation>
</ref>
<ref id="B115">
<label>115</label><nlm-citation citation-type="">
<collab>ESMO Clinical Practice Guidelines:Breast Cancer Guidelines [Internet]</collab>
<source><![CDATA[European Society for Medical Oncology AQ2]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B116">
<label>116</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amor Pan]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Barón Duarte]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Regueiro García]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bioética y oncología. Una puerta abierta a la oportunidad]]></article-title>
<source><![CDATA[Sociedad Oncológica de Galicia]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B117">
<label>117</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carbine]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Lostumbo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Wallace]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk-reducing mastectomy for the prevention of primary breast cancer]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2018</year>
<volume>4</volume>
<page-range>CD002748</page-range></nlm-citation>
</ref>
<ref id="B118">
<label>118</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Franceschini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Di Leone]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Terribile]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bilateral prophylactic mastectomy in BRCA mutation carriers:what surgeons need to know]]></article-title>
<source><![CDATA[Ann Ital Chir]]></source>
<year>2019</year>
<volume>90</volume>
<page-range>1-2</page-range></nlm-citation>
</ref>
<ref id="B119">
<label>119</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Srethbhakdi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Brennan]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Hamid]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Contralateral prophylactic mastectomy for unilateral breast cancer in women at average risk:Systematic review of patient reported outcomes]]></article-title>
<source><![CDATA[Psychooncology]]></source>
<year>2020</year>
<volume>29</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>960-73</page-range></nlm-citation>
</ref>
<ref id="B120">
<label>120</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lopez]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Bluebond-Langner]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Houssock]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Plastic and reconstructive surgeons'knowledge and comfort of contralateral prophylactic mastectomy:A survey of the American Society of Plastic Surgeons]]></article-title>
<source><![CDATA[Front Oncol]]></source>
<year>2019</year>
<volume>8</volume>
<page-range>647</page-range></nlm-citation>
</ref>
<ref id="B121">
<label>121</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nagaraja]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Edirimanne]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Eslick]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is sentinel lymph node biopsy necessary in patients undergoing prophylactic mastectomy?A systematic review and meta-analysis]]></article-title>
<source><![CDATA[Breast J]]></source>
<year>2016</year>
<volume>22</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>158-65</page-range></nlm-citation>
</ref>
<ref id="B122">
<label>122</label><nlm-citation citation-type="journal">
<collab>Early Breast Cancer Trialists'Collaborative Group (EBCTCG)</collab>
<article-title xml:lang=""><![CDATA[Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:an overview of the randomized trials]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2005</year>
<volume>365</volume>
<page-range>1687-717</page-range></nlm-citation>
</ref>
<ref id="B123">
<label>123</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sparano]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Gray]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Makower]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Pritchard]]></surname>
<given-names><![CDATA[KI]]></given-names>
</name>
<name>
<surname><![CDATA[Albain]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Hayes]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adjuvant chemotherapy guided by a 21 gene expression assay in breast cancer]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2018</year>
<volume>379</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>111-21</page-range></nlm-citation>
</ref>
<ref id="B124">
<label>124</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[C]]></surname>
<given-names><![CDATA[Davies]]></given-names>
</name>
<name>
<surname><![CDATA[J]]></surname>
<given-names><![CDATA[Godwin]]></given-names>
</name>
<name>
<surname><![CDATA[R]]></surname>
<given-names><![CDATA[Gray]]></given-names>
</name>
<name>
<surname><![CDATA[H]]></surname>
<given-names><![CDATA[C Pan]]></given-names>
</name>
<name>
<surname><![CDATA[M]]></surname>
<given-names><![CDATA[Clarke]]></given-names>
</name>
</person-group>
<collab>Early Breast Cancer Trialists'Collaborative Group (EBCTCG);R Peto</collab>
<article-title xml:lang=""><![CDATA[Comparisons between different polychemotherapy regimens for early breast cancer:meta-analyses of long-term outcome among 100,000 women in 123 randomized trials]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2012</year>
<volume>379</volume>
<page-range>432-44</page-range></nlm-citation>
</ref>
<ref id="B125">
<label>125</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gradishar]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[BO]]></given-names>
</name>
<name>
<surname><![CDATA[Balassanian]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Breast cancer, version 4.2017, NCCN Clinical Practice Guidelines in Oncology]]></article-title>
<source><![CDATA[J Natl Compr Canc Netw]]></source>
<year>2018</year>
<volume>16</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>310-20</page-range></nlm-citation>
</ref>
<ref id="B126">
<label>126</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aebi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Davidson]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Gruber]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary breast cancer:ESMO clinical practice guidelines for diagnosis, treatment and follow-up]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2011</year>
<volume>22</volume>
<numero>(suppl 6)</numero>
<issue>(suppl 6)</issue>
<page-range>vi12-24</page-range></nlm-citation>
</ref>
<ref id="B127">
<label>127</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goldhirsch]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wood]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
<name>
<surname><![CDATA[Coates]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2011</year>
<volume>22</volume>
<page-range>1736-47</page-range></nlm-citation>
</ref>
<ref id="B128">
<label>128</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chavez-MacGregor]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Lichtensztajn]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Delayed initiation of adjuvant chemotherapy among patients with breast cancer]]></article-title>
<source><![CDATA[JAMA Oncol]]></source>
<year>2016</year>
<volume>2</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>322-9</page-range></nlm-citation>
</ref>
<ref id="B129">
<label>129</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morante]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Araujo]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of the delayed initiation of adjuvant chemotherapy in the outcomes of triple negative breast cancer]]></article-title>
<source><![CDATA[Clin Breast Cancer]]></source>
<year>2021</year>
<volume>21</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>239-46.e4</page-range></nlm-citation>
</ref>
<ref id="B130">
<label>130</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferguson]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Wilcken]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Vagg]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ghersi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Nowak]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Taxanes for adjuvant treatment of early breast cancer]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2007</year>
<volume>4</volume>
<page-range>CD004421</page-range></nlm-citation>
</ref>
<ref id="B131">
<label>131</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Willson]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Burke]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ferguson]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ghersi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Nowak]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Wilcken]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Taxane-based combinations as adjuvant chemotherapy of early breast cancer:a meta-analysis of randomized trials]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2008</year>
<volume>26</volume>
<page-range>44-53</page-range></nlm-citation>
</ref>
<ref id="B132">
<label>132</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sparano]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Martino]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term follow-up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2015</year>
<volume>33</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>2353-60</page-range></nlm-citation>
</ref>
<ref id="B133">
<label>133</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sparano]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martino]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Weekly paclitaxel in the adjuvant treatment of breast cancer]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2008</year>
<volume>358</volume>
<page-range>1663-71</page-range></nlm-citation>
</ref>
<ref id="B134">
<label>134</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[von Minckwitz]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Raab]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Caputo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer:the GEPARDUO study of the German Breast Group]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2005</year>
<volume>23</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2676-85</page-range></nlm-citation>
</ref>
<ref id="B135">
<label>135</label><nlm-citation citation-type="journal">
<collab>NCCN linical Practice Guidelines in Oncology</collab>
<article-title xml:lang=""><![CDATA[Breast Cancer]]></article-title>
<source><![CDATA[Version 2.2023. National Comprehensive Cancer Network;February 7]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B136">
<label>136</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Masuda]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ohtani]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Im]]></surname>
<given-names><![CDATA[YH]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Yokota]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adjuvant capecitabine for breast cancer after preoperative chemotherapy]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2017</year>
<volume>376</volume>
<page-range>2147-59</page-range></nlm-citation>
</ref>
<ref id="B137">
<label>137</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Geyer Jr]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Bandos]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Rastogi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer:the NSABP B-36 trial (NRG Oncology)]]></article-title>
<source><![CDATA[Breast Cancer Res Treat]]></source>
<year>2022</year>
<volume>193</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>555-64</page-range></nlm-citation>
</ref>
<ref id="B138">
<label>138</label><nlm-citation citation-type="journal">
<collab>Early Breast Cancer Trialists'Collaborative Group</collab>
<article-title xml:lang=""><![CDATA[Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen:patient level meta-analysis of randomised trials]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2011</year>
<volume>378</volume>
<page-range>771-84</page-range></nlm-citation>
</ref>
<ref id="B139">
<label>139</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Metzger Filho]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Giobbie-Hurder]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mallon]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2015</year>
<volume>33</volume>
<page-range>2772-9</page-range></nlm-citation>
</ref>
<ref id="B140">
<label>140</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Forbes]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Sestak]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Howell]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[IBIS-II investigators Anastrazole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS):a double-blind, randomised controlled trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2016</year>
<volume>387</volume>
<numero>10021</numero>
<issue>10021</issue>
<page-range>866-73</page-range></nlm-citation>
</ref>
<ref id="B141">
<label>141</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cuzick]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sestak]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Pinder]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ:long-term results from the UK/ANZ DCIS trial]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2011</year>
<volume>12</volume>
<page-range>21-9</page-range></nlm-citation>
</ref>
<ref id="B142">
<label>142</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wapnir]]></surname>
<given-names><![CDATA[IL]]></given-names>
</name>
<name>
<surname><![CDATA[Dignam]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long term-outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-27 and B-24 randomized clinical trials for DCIS]]></article-title>
<source><![CDATA[J Natl Cancer Inst]]></source>
<year>2011</year>
<volume>103</volume>
<page-range>478-88</page-range></nlm-citation>
</ref>
<ref id="B143">
<label>143</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Costantino]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Wickerham]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tamoxifen for the prevention of breast cancer:current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study]]></article-title>
<source><![CDATA[J Natl Cancer Inst]]></source>
<year>2005</year>
<volume>97</volume>
<page-range>1652-62</page-range></nlm-citation>
</ref>
<ref id="B144">
<label>144</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Margolese]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anastrazole versus tamoxifen in postmenopausal women in ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSAB B-35):a randomised, double-blind, phase 3 clinical trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2016</year>
<volume>387</volume>
<page-range>845</page-range></nlm-citation>
</ref>
<ref id="B145">
<label>145</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sella]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ruddy]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Carey]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimal endocrine therapy in premenopausal women:a pragmatic approach to unanswered questions]]></article-title>
<source><![CDATA[JCO Oncol Pract]]></source>
<year>2022</year>
<volume>18</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>211-6</page-range></nlm-citation>
</ref>
<ref id="B146">
<label>146</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Pan]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Godwin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gray]]></surname>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adjuvant tamoxifen:longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer:ATLAS, a randomised trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2013</year>
<volume>381</volume>
<numero>9869</numero>
<issue>9869</issue>
<page-range>805-16</page-range></nlm-citation>
</ref>
<ref id="B147">
<label>147</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Francis]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Pagani]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Fleming]]></surname>
<given-names><![CDATA[GF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tailoring adjuvant endocrine therapy for premenopausal breast cancer]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2018</year>
<volume>379</volume>
<page-range>122-37</page-range></nlm-citation>
</ref>
<ref id="B148">
<label>148</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pagani]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Francis]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Fleming]]></surname>
<given-names><![CDATA[GF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Absolute improvement in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women:results from TEXT and SOFT]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2020</year>
<volume>38</volume>
<page-range>1293-303</page-range></nlm-citation>
</ref>
<ref id="B149">
<label>149</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andre]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ismaila]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Allison]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer:ASCO Guideline Update]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2022</year>
<volume>40</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>1816-37</page-range></nlm-citation>
</ref>
<ref id="B150">
<label>150</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johnston]]></surname>
<given-names><![CDATA[SRD]]></given-names>
</name>
<name>
<surname><![CDATA[Toi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[O'Shaughnessy]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE):results from a preplanned interim analysis of a randomised, open-label, phase 3 trial]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2023</year>
<volume>24</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>77-90</page-range></nlm-citation>
</ref>
<ref id="B151">
<label>151</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giordano]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Freedman]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Somerfield]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Expert Panel. Abemaciclib with endocrine therapy in the treatment of high-risk early breast cancer:ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2022</year>
<volume>40</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>307-9</page-range></nlm-citation>
</ref>
<ref id="B152">
<label>152</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Burstein]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Somerfield]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Barton]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer:ASCO Guideline update]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2021</year>
<volume>39</volume>
<numero>35</numero>
<issue>35</issue>
<page-range>3959-77</page-range></nlm-citation>
</ref>
<ref id="B153">
<label>153</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bartlett]]></surname>
<given-names><![CDATA[JMS]]></given-names>
</name>
<name>
<surname><![CDATA[Sgroi]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Treuner]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Breast cancer index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the adjuvant tamoxifen-to offer more?(aTTom) trial]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2019</year>
<volume>30</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1776-83</page-range></nlm-citation>
</ref>
<ref id="B154">
<label>154</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goss]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Ingle]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
<name>
<surname><![CDATA[Pritchard]]></surname>
<given-names><![CDATA[KI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Extending aromatase-inhibitor adjuvant therapy to 10 years]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2016</year>
<volume>375</volume>
<page-range>209-19</page-range></nlm-citation>
</ref>
<ref id="B155">
<label>155</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blok]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kroep]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Meershoek-Klein Kranenbarg]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimal duration of extended adjuvant endocrine therapy for early breast cancer:Results of the IDEAL trial (BOOG 2006 05)]]></article-title>
<source><![CDATA[J Natl Cancer Inst]]></source>
<year>2018</year>
<volume>110</volume>
<numero>(1)</numero>
<issue>(1)</issue>
</nlm-citation>
</ref>
<ref id="B156">
<label>156</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tjan-Heijnen]]></surname>
<given-names><![CDATA[VCG]]></given-names>
</name>
<name>
<surname><![CDATA[van Hellemond]]></surname>
<given-names><![CDATA[IEG]]></given-names>
</name>
<name>
<surname><![CDATA[Peer]]></surname>
<given-names><![CDATA[PGM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA):A randomised, phase 3 trial]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2017</year>
<volume>18</volume>
<page-range>1502-11</page-range></nlm-citation>
</ref>
<ref id="B157">
<label>157</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Colleoni]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Luo]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Karlsson]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE):A multicentre, open-label, randomised, phase 3 trial]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2018</year>
<volume>19</volume>
<page-range>127-38</page-range></nlm-citation>
</ref>
<ref id="B158">
<label>158</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zardavas]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Tryfonidis]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Goulioti]]></surname>
<given-names><![CDATA[T M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Targeted adjuvant therapy in breast cancer]]></article-title>
<source><![CDATA[Exp Rev Anticancer Ther]]></source>
<year>2016</year>
<volume>16</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1263-75</page-range></nlm-citation>
</ref>
<ref id="B159">
<label>159</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dahabreh]]></surname>
<given-names><![CDATA[IJ]]></given-names>
</name>
<name>
<surname><![CDATA[Linardou]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Siannis]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trastuzumab in the adjuvant treatment of early-stage breast cancer:a systematic review and metaanalysis of randomized controlled trials]]></article-title>
<source><![CDATA[Oncologist]]></source>
<year>2008</year>
<volume>13</volume>
<page-range>620-30</page-range></nlm-citation>
</ref>
<ref id="B160">
<label>160</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gianni]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Dafni]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Gelber]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer:a 4-year follow-up of a randomized controlled trial]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2011</year>
<volume>12</volume>
<page-range>236-44</page-range></nlm-citation>
</ref>
<ref id="B161">
<label>161</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Romond]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Suman]]></surname>
<given-names><![CDATA[VJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer:planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2014</year>
<volume>32</volume>
<numero>33</numero>
<issue>33</issue>
<page-range>3744-52</page-range></nlm-citation>
</ref>
<ref id="B162">
<label>162</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lambertini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pondé]]></surname>
<given-names><![CDATA[NF]]></given-names>
</name>
<name>
<surname><![CDATA[Solinas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adjuvant trastuzumab:a 10 year overview of its benefit]]></article-title>
<source><![CDATA[Exp Rev Anticancer Ther]]></source>
<year>2017</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>61-74</page-range></nlm-citation>
</ref>
<ref id="B163">
<label>163</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Slamon]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Eiermann]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Robert]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ten year follow-up of the BCIRG-006 trial comparing doxorubicin plus cyclophosphamide followed by docetaxel (ACT) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+early breast cancer patients]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>2018</year>
<volume>76</volume>
<numero>(4 Suppl)</numero>
<issue>(4 Suppl)</issue>
</nlm-citation>
</ref>
<ref id="B164">
<label>164</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perez]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Suman]]></surname>
<given-names><![CDATA[VJ]]></given-names>
</name>
<name>
<surname><![CDATA[Davidson]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2011</year>
<volume>29</volume>
<page-range>4491-7</page-range></nlm-citation>
</ref>
<ref id="B165">
<label>165</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jackisch]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Piccart]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gelber]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HERA trial:10 years follow up of trastuzumab after adjuvant chemotherapy in HER2 positive early breast cancer Final analysis]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>2016</year>
<volume>76</volume>
<numero>(4 Suppl)</numero>
<issue>(4 Suppl)</issue>
</nlm-citation>
</ref>
<ref id="B166">
<label>166</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pivot]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Romieu]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Debled]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE):a randomized phase 3 trial]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2013</year>
<volume>14</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>741-8</page-range></nlm-citation>
</ref>
<ref id="B167">
<label>167</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tolaney]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Barry]]></surname>
<given-names><![CDATA[WT]]></given-names>
</name>
<name>
<surname><![CDATA[Dang]]></surname>
<given-names><![CDATA[CT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adjuvant paclitaxel and trastuzumab for nodenegative, HER2-positive breast cancer]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2015</year>
<volume>372</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>134-41</page-range></nlm-citation>
</ref>
<ref id="B168">
<label>168</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Von Minckwitz]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Procter]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[de Azambuja]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2017</year>
<volume>377</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>122-31</page-range></nlm-citation>
</ref>
<ref id="B169">
<label>169</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Piccart]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Procter]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fumagalli]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interim overall survival analysis of APHINITY (BIG 4-11):A randomized multicenter, double-blind, placebo controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>2020</year>
<volume>80</volume>
<numero>(4 Suppl)</numero>
<issue>(4 Suppl)</issue>
</nlm-citation>
</ref>
<ref id="B170">
<label>170</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Loibl]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[German Breast Group (GBG). Updated results of APHINITY at 8.4 years median follow-up]]></article-title>
<source><![CDATA[ESMO Virtual Plenary, July 14,]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B171">
<label>171</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Delaloge]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Holmes]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET):a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2016</year>
<volume>17</volume>
<page-range>367-77</page-range></nlm-citation>
</ref>
<ref id="B172">
<label>172</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Holmes]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Ejlertsen]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET):5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2017</year>
<volume>18</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1688-700</page-range></nlm-citation>
</ref>
<ref id="B173">
<label>173</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Moy]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mansi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial]]></article-title>
<source><![CDATA[Clin Breast Cancer]]></source>
<year>2021</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>80-91</page-range></nlm-citation>
</ref>
<ref id="B174">
<label>174</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tutt]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Garber]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kaufman]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adjuvant olaparib for patients with BRCA1or BRCA2-mutated breast cancer]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2021</year>
<volume>384</volume>
<page-range>2394-405</page-range></nlm-citation>
</ref>
<ref id="B175">
<label>175</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Geyer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Garber]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gelber]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2022</year>
<volume>33</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1250-68</page-range></nlm-citation>
</ref>
<ref id="B176">
<label>176</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sparano]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Gray]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Makower]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trial Assigning Individualized Options for Treatment (TAILORx):An Update Including 12-year event rates]]></article-title>
<source><![CDATA[San Antonio Breast Cancer Symposium, Dec 6]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B177">
<label>177</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Piccart]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[van't Veer]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Poncet]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[70-gene signature as an aid for treatment decisions in early breast cancer:updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2021</year>
<volume>22</volume>
<page-range>476-88</page-range></nlm-citation>
</ref>
<ref id="B178">
<label>178</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sestak]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Martín]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dubsky]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone]]></article-title>
<source><![CDATA[Breast Cancer Res Treat]]></source>
<year>2019</year>
<volume>176</volume>
<page-range>377-86</page-range></nlm-citation>
</ref>
<ref id="B179">
<label>179</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Filipits]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rudas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jakesz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors]]></article-title>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2011</year>
<volume>17</volume>
<page-range>6012-20</page-range></nlm-citation>
</ref>
<ref id="B180">
<label>180</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laenkholm]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Eriksen]]></surname>
<given-names><![CDATA[JO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PAM50 risk of recurrence score predicts 10-year distant recurrence in a comprehensive Danish cohort of postmenopausal women allocated to 5 years of endocrine therapy for hormone receptor-positive early breast cancer]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2018</year>
<volume>36</volume>
<page-range>735-40</page-range></nlm-citation>
</ref>
<ref id="B181">
<label>181</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De la Cruz]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Karamchandani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chambergo-Michilot]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Does breast-conserving surgery with radiotherapy have a better survival than mastectomy?A meta-analysis of more than 1,500,000 patients]]></article-title>
<source><![CDATA[Ann Surg Oncol]]></source>
<year>2022</year>
<volume>29</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>6163-88</page-range></nlm-citation>
</ref>
<ref id="B182">
<label>182</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chagpar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors associated with a delay in postmastectomy radiation therapy]]></article-title>
<source><![CDATA[Am Surg]]></source>
<year>2021</year>
<volume>87</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1484-7</page-range></nlm-citation>
</ref>
<ref id="B183">
<label>183</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bleicher]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Moran]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ruth]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The impact of radiotherapy delay in breast conservation patients not receiving chemotherapy and the rationale for dichotomizing the radiation oncology time-dependent standard into two quality measures]]></article-title>
<source><![CDATA[Ann Surg Oncol]]></source>
<year>2022</year>
<volume>29</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>469-81</page-range></nlm-citation>
</ref>
<ref id="B184">
<label>184</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jobsen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Struikmans]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[van der Palen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical relevance of the timing of radiotherapy after breast-conserving surgery:Results of a large, single-centre, population-based cohort study]]></article-title>
<source><![CDATA[Strahlenther Onkol]]></source>
<year>2022</year>
<volume>198</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>268-81</page-range></nlm-citation>
</ref>
<ref id="B185">
<label>185</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meattini]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Becherini]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Boersma]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2022</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>e31</page-range></nlm-citation>
</ref>
<ref id="B186">
<label>186</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hickey]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Lehman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Partial breast irradiation versus whole breast radiotherapy for early breast cancer]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2021</year>
<volume>8</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>CD007077</page-range></nlm-citation>
</ref>
<ref id="B187">
<label>187</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Arthur]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hannoun-Levi]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Partial breast irradiation:An updated consensus statement from the American brachytherapy society]]></article-title>
<source><![CDATA[Brachytherapy]]></source>
<year>2022</year>
<volume>21</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>726-47</page-range></nlm-citation>
</ref>
<ref id="B188">
<label>188</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Burstein]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Curigliano]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Thürlimann]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Customizing local and systemic therapies for women with early breast cancer:the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2021</year>
<volume>32</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1216-35</page-range></nlm-citation>
</ref>
<ref id="B189">
<label>189</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hennequin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Belkacémi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Bourgier]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiotherapy of breast cancer]]></article-title>
<source><![CDATA[Cancer Radiother]]></source>
<year>2022</year>
<volume>26</volume>
<numero>(1-2)</numero>
<issue>(1-2)</issue>
<page-range>221-30</page-range></nlm-citation>
</ref>
<ref id="B190">
<label>190</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beddok]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kirova]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Laki]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The place of the boost in the breast cancer treatment:State of art]]></article-title>
<source><![CDATA[Radiother Oncol]]></source>
<year>2022</year>
<volume>170</volume>
<page-range>55-63</page-range></nlm-citation>
</ref>
<ref id="B191">
<label>191</label><nlm-citation citation-type="journal">
<collab>NCCN Clinical Practice Guidelines in Oncology</collab>
<article-title xml:lang=""><![CDATA[Breast Cancer]]></article-title>
<source><![CDATA[Version 1.2023 [Internet]. National Comprehensive Cancer Network]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B192">
<label>192</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perera]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Baldassarre]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Eisen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A systematic review of axillary nodal irradiation for the management of the axilla in patients with early-stage breast cancer]]></article-title>
<source><![CDATA[Surg Oncol]]></source>
<year>2022</year>
<volume>42</volume>
<page-range>101754</page-range></nlm-citation>
</ref>
<ref id="B193">
<label>193</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brackstone]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Baldassarre]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Perera]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of the axilla in early-stage breast cancer:Ontario Health (Cancer Care Ontario) and ASCO Guideline]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2021</year>
<volume>39</volume>
<numero>27</numero>
<issue>27</issue>
<page-range>3056-82</page-range></nlm-citation>
</ref>
<ref id="B194">
<label>194</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Speers]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Jagsi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tailoring the omission of radiotherapy for early-stage breast cancer based on tumor biology]]></article-title>
<source><![CDATA[Semin Radiat Oncol]]></source>
<year>2022</year>
<volume>32</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>198-206</page-range></nlm-citation>
</ref>
<ref id="B195">
<label>195</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Overgaard]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nielsen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Tramm]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Postmastectomy radiotherapy in high-risk breast cancer patients given adjuvant systemic therapy. A 30-year long-term report from the Danish breast cancer cooperative group DBCG 82bc trial]]></article-title>
<source><![CDATA[Radiother Oncol]]></source>
<year>2022</year>
<volume>170</volume>
<page-range>4-13</page-range></nlm-citation>
</ref>
<ref id="B196">
<label>196</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fodor]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Brombin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mangili]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost:Should the indications for radiotherapy be more personalized?]]></article-title>
<source><![CDATA[Breast]]></source>
<year>2021</year>
<volume>55</volume>
<page-range>45-54</page-range></nlm-citation>
</ref>
<ref id="B197">
<label>197</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paluch-Shimon]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cardoso]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Partridge]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2022</year>
<volume>33</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1097-118</page-range></nlm-citation>
</ref>
<ref id="B198">
<label>198</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sibilio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Curcio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Toesca]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Local treatment in patients with hereditary breast cancer:decision-making process in low-, moderate-, high-penetrance pathogenic germline mutation carriers]]></article-title>
<source><![CDATA[Curr Opin Oncol]]></source>
<year>2022</year>
<volume>34</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>614-22</page-range></nlm-citation>
</ref>
<ref id="B199">
<label>199</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[BV]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Breast radiation therapy-related treatment outcomes in patients with or without germline mutations on multigene panel testing]]></article-title>
<source><![CDATA[Int J Radiat Oncol Biol Phys]]></source>
<year>2022</year>
<volume>112</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>437-44</page-range></nlm-citation>
</ref>
<ref id="B200">
<label>200</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lazzari]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Buono]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Zannino]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Breast cancer adjuvant radiotherapy in BRCA1/2, TP53, ATM genes mutations:are there solved issues?]]></article-title>
<source><![CDATA[Breast Cancer (Dove Medical Press)]]></source>
<year>2021</year>
<volume>13</volume>
<page-range>299-310</page-range></nlm-citation>
</ref>
<ref id="B201">
<label>201</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trombetta]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Dragun]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mayr]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ASTRO radiation therapy summary of the ASCO-ASTRO-SSO guideline on management of hereditary breast cancer]]></article-title>
<source><![CDATA[Pract Radiat Oncol]]></source>
<year>2020</year>
<volume>10</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>235-42</page-range></nlm-citation>
</ref>
<ref id="B202">
<label>202</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yip]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Newman]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline for Management of Hereditary Breast Cancer]]></article-title>
<source><![CDATA[JAMA Surg]]></source>
<year>2021</year>
<volume>156</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>284-5</page-range></nlm-citation>
</ref>
<ref id="B203">
<label>203</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goel]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A systematic review exploring the role of modern radiation for the treatment of hereditary or familial breast cancer]]></article-title>
<source><![CDATA[Radiother Oncol]]></source>
<year>2022</year>
<volume>176</volume>
<page-range>59-67</page-range></nlm-citation>
</ref>
<ref id="B204">
<label>204</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thariat]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chevalier]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Orbach]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Avoidance or adaptation of radiotherapy in patients with cancer with Li-Fraumeni and heritable TP53-related cancer syndromes]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2021</year>
<volume>22</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>e574</page-range></nlm-citation>
</ref>
<ref id="B205">
<label>205</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beddok]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cottu]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Fourquet]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combination of modern radiotherapy and new targeted treatments for breast cancer management]]></article-title>
<source><![CDATA[Cancers (Basel)]]></source>
<year>2021</year>
<volume>13</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>6358</page-range></nlm-citation>
</ref>
<ref id="B206">
<label>206</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jungles]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Holcomb]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Pearson]]></surname>
<given-names><![CDATA[AN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer]]></article-title>
<source><![CDATA[Front Oncol]]></source>
<year>2022</year>
<volume>12</volume>
<page-range>1022542</page-range></nlm-citation>
</ref>
<ref id="B207">
<label>207</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiotherapy combined with immunotherapy:the dawn of cancer treatment]]></article-title>
<source><![CDATA[Signal Transduct Target Ther]]></source>
<year>2022</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>258</page-range></nlm-citation>
</ref>
<ref id="B208">
<label>208</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Santa-Maria]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Dunn]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[AY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunotherapy combined with radiation therapy in breast cancer:a rapidly evolving landscape]]></article-title>
<source><![CDATA[Semin Radiat Oncol]]></source>
<year>2022</year>
<volume>32</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>291-7</page-range></nlm-citation>
</ref>
<ref id="B209">
<label>209</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ciérvide]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preoperative radio(chemo)therapy in breast cancer:time to switch the perspective?]]></article-title>
<source><![CDATA[Curr Oncol]]></source>
<year>2022</year>
<volume>29</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>9767-87</page-range></nlm-citation>
</ref>
<ref id="B210">
<label>210</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ciérvide]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Montero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[García-Rico]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary chemoradiotherapy treatment (PCRT) for HER2+and triple negative breast cancer patients:a feasible combination]]></article-title>
<source><![CDATA[Cancers (Basel)]]></source>
<year>2022</year>
<volume>14</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>4531</page-range></nlm-citation>
</ref>
<ref id="B211">
<label>211</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pan]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Yao]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term outcomes of preoperative radiotherapy in locally advanced breast cancer:Analysis of Surveillance, Epidemiology, and End Results (SEER) database]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2020</year>
<volume>38</volume>
<numero>15(suppl)</numero>
<issue>15(suppl)</issue>
</nlm-citation>
</ref>
<ref id="B212">
<label>212</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pedersen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Esen]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mellemkjær]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The incidence of breast cancer recurrence 10-32 years after primary diagnosis]]></article-title>
<source><![CDATA[J Natl Cancer Inst]]></source>
<year>2022</year>
<volume>114</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>391-9</page-range></nlm-citation>
</ref>
<ref id="B213">
<label>213</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hardy-Abeloos]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Xiao]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Oh]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early effectiveness and toxicity outcomes of reirradiation after breast conserving surgery for recurrent or new primary breast cancer]]></article-title>
<source><![CDATA[Breast Cancer Res Treat]]></source>
<year>2023</year>
<volume>198</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>43-51</page-range></nlm-citation>
</ref>
<ref id="B214">
<label>214</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Michalet]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dejean]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Schick]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiotherapy and pregnancy]]></article-title>
<source><![CDATA[Cancer Radiother]]></source>
<year>2022</year>
<volume>26</volume>
<numero>(1-2)</numero>
<issue>(1-2)</issue>
<page-range>417-23</page-range></nlm-citation>
</ref>
<ref id="B215">
<label>215</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Loibl]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Denkert]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[von Minckwitz]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neoadjuvant treatment of breast cancer-Clinical and research perspective]]></article-title>
<source><![CDATA[Breast]]></source>
<year>2015</year>
<volume>24</volume>
<numero>(Suppl 2)</numero>
<issue>(Suppl 2)</issue>
<page-range>S73-7</page-range></nlm-citation>
</ref>
<ref id="B216">
<label>216</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kodali]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gadi]]></surname>
<given-names><![CDATA[VK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preoperative systemic therapy for breast cancer]]></article-title>
<source><![CDATA[Surg Clin North Am]]></source>
<year>2023</year>
<volume>103</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>201-17</page-range></nlm-citation>
</ref>
<ref id="B217">
<label>217</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caudle]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Bedrosian]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Milton]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of sentinel lymph node dissection after neoadjuvant chemotherapy in patients with node-positive breast cancer at diagnosis:practice patterns of American Society of Breast Surgeons Members]]></article-title>
<source><![CDATA[Ann Surg Oncol]]></source>
<year>2017</year>
<volume>24</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2925-34</page-range></nlm-citation>
</ref>
<ref id="B218">
<label>218</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chiba]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hoskin]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
<name>
<surname><![CDATA[Hallberg]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact that timing of genetic mutation diagnosis has on surgical decision making and outcome for BRCA1/BRCA2 mutation carriers with breast cancer]]></article-title>
<source><![CDATA[Ann Surg Oncol]]></source>
<year>2016</year>
<volume>23</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>3232-8</page-range></nlm-citation>
</ref>
<ref id="B219">
<label>219</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lambertini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[HCF]]></given-names>
</name>
<name>
<surname><![CDATA[Leonard]]></surname>
<given-names><![CDATA[RCF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer:a systematic review and meta-analysis of individual patient-level data]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2018</year>
<volume>36</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>1981-90</page-range></nlm-citation>
</ref>
<ref id="B220">
<label>220</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Korde]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Somerfield]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Carey]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer:ASCO Guideline]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2021</year>
<volume>39</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>1485-505</page-range></nlm-citation>
</ref>
<ref id="B221">
<label>221</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[von Minckwitz]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Untch]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nüesch]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of treatment characteristics on response of different breast cancer phenotypes:pooled analysis of the German neo-adjuvant chemotherapy trials]]></article-title>
<source><![CDATA[Breast Cancer Res Treat]]></source>
<year>2011</year>
<volume>125</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>145-56</page-range></nlm-citation>
</ref>
<ref id="B222">
<label>222</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wright]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Contemporary approaches to the axilla in breast cancer]]></article-title>
<source><![CDATA[Am J Surg]]></source>
<year>2023</year>
<volume>225</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>583-7</page-range></nlm-citation>
</ref>
<ref id="B223">
<label>223</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cain]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Macpherson]]></surname>
<given-names><![CDATA[IR]]></given-names>
</name>
<name>
<surname><![CDATA[Beresford]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neoadjuvant therapy in early breast cancer:treatment considerations and common debates in practice]]></article-title>
<source><![CDATA[Clin Oncol (R Coll Radiol)]]></source>
<year>2017</year>
<volume>29</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>642-52</page-range></nlm-citation>
</ref>
<ref id="B224">
<label>224</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schmid]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cortes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pusztai]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pembrolizumab for early triple-negative breast cancer]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2020</year>
<volume>382</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>810-21</page-range></nlm-citation>
</ref>
<ref id="B225">
<label>225</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Allevi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Strina]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Andreis]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer]]></article-title>
<source><![CDATA[Br J Cancer]]></source>
<year>2013</year>
<volume>108</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1587-92</page-range></nlm-citation>
</ref>
<ref id="B226">
<label>226</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montagna]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sevilimedu]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Fornier]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[How effective is Neoadjuvant Endocrine Therapy (NET) in downstaging the axilla and achieving breast-conserving surgery?]]></article-title>
<source><![CDATA[Ann Surg Oncol]]></source>
<year>2020</year>
<volume>27</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>4702-10</page-range></nlm-citation>
</ref>
<ref id="B227">
<label>227</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stafford]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Edmiston]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Axillary response in patients undergoing neoadjuvant endocrine treatment for node-positive breast cancer:systematic literature review and NCDB analysis]]></article-title>
<source><![CDATA[Ann Surg Oncol]]></source>
<year>2020</year>
<volume>27</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>4669-77</page-range></nlm-citation>
</ref>
<ref id="B228">
<label>228</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barchiesi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mazzotta]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Krasniqi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neoadjuvant endocrine therapy in breast cancer:Current knowledge and future perspectives]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2020</year>
<volume>21</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>3528</page-range></nlm-citation>
</ref>
<ref id="B229">
<label>229</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goorts]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Dreuning]]></surname>
<given-names><![CDATA[KMA]]></given-names>
</name>
<name>
<surname><![CDATA[Houwers]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer]]></article-title>
<source><![CDATA[Breast Cancer Res]]></source>
<year>2018</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>34</page-range></nlm-citation>
</ref>
<ref id="B230">
<label>230</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scheel]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Partridge]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MRI, clinical examination, and mammography for preoperative assessment of residual disease and pathologic complete response after neoadjuvant chemotherapy for breast cancer:ACRIN 6657 trial]]></article-title>
<source><![CDATA[AJR Am J Roentgenol]]></source>
<year>2018</year>
<volume>210</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>13761385</page-range></nlm-citation>
</ref>
<ref id="B231">
<label>231</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Law]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Cao]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Wright]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adequacy of invasive and in situ breast carcinoma margins in radioactive seed and wire-guided localization lumpectomies]]></article-title>
<source><![CDATA[Breast J]]></source>
<year>2021</year>
<volume>27</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>134-40</page-range></nlm-citation>
</ref>
<ref id="B232">
<label>232</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Petruolo]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Sevilimedu]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Montagna]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[How often does modern neoadjuvant chemotherapy downstage patients to breast-conserving surgery?]]></article-title>
<source><![CDATA[Ann Surg Oncol]]></source>
<year>2021</year>
<volume>28</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>287-94</page-range></nlm-citation>
</ref>
<ref id="B233">
<label>233</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caudle]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer]]></article-title>
<source><![CDATA[Ann Surg Oncol]]></source>
<year>2011</year>
<volume>18</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>932-8</page-range></nlm-citation>
</ref>
<ref id="B234">
<label>234</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[XB]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Rong]]></surname>
<given-names><![CDATA[QL]]></given-names>
</name>
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Postmastectomy radiation therapy based on pathologic nodal status in clinical node-positive stage II to III breast cancer treated with neoadjuvant chemotherapy]]></article-title>
<source><![CDATA[Int J Radiat Oncol Biol Phys]]></source>
<year>2020</year>
<volume>108</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1030-9</page-range></nlm-citation>
</ref>
<ref id="B235">
<label>235</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krug]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lederer]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Seither]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Post-mastectomy radiotherapy after neoadjuvant chemotherapy in breast cancer:a pooled retrospective analysis of three prospective randomized trials]]></article-title>
<source><![CDATA[Ann Surg Oncol]]></source>
<year>2019</year>
<volume>26</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>3892-901</page-range></nlm-citation>
</ref>
<ref id="B236">
<label>236</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marino]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lancellotta]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Franco]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Loco-regional adjuvant radiation therapy in breast cancer patients with positive axillary lymph-nodes at diagnosis (CN2) undergoing preoperative chemotherapy and with complete pathological lymph-nodes response]]></article-title>
<source><![CDATA[Development of GRADE (Grades of recommendation, assessment, Development and Evaluation) recommendation by the Italian Association of radiation therapy and Clinical Oncology (AIRO). Breast]]></source>
<year>2021</year>
<volume>55</volume>
<page-range>119-27</page-range></nlm-citation>
</ref>
<ref id="B237">
<label>237</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Belkacemi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Debbi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Loganadane]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiothérapie adjuvante et néoadjuvante des cancers du sein:mise au point sur les données de lalittérature disponibles en 2020]]></article-title>
<source><![CDATA[Cancer Radiother]]></source>
<year>2020</year>
<volume>24</volume>
<numero>67</numero>
<issue>67</issue>
<page-range>482-92</page-range></nlm-citation>
</ref>
<ref id="B238">
<label>238</label><nlm-citation citation-type="journal">
<collab>U S. National Library of Medicine, Clinical-Trials.gov</collab>
<article-title xml:lang=""><![CDATA[National Cancer Institute, Radiation Therapy Oncology Group]]></article-title>
<source><![CDATA[Standard for comprehensive radiation therapy in treating patients with early-stage breast cancer previously treated with chemotherapy and surgery. Identifier NCT01872975 [Internet]]]></source>
<year></year>
<publisher-loc><![CDATA[U. S ]]></publisher-loc>
<publisher-name><![CDATA[National Library of Medicine, Clinical-Trials.gov]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B239">
<label>239</label><nlm-citation citation-type="journal">
<collab>U S. National Library of Medicine, ClinicalTrials.gov</collab>
<article-title xml:lang=""><![CDATA[National Cancer Institute, Canadian Cancer Trials Group]]></article-title>
<source><![CDATA[Comparison of axillary lymph node dissection with axillary radiation for patients with node-positive breast cancer related with chemotherapy. Identifier:NCT01901094 [Internet]]]></source>
<year></year>
<publisher-loc><![CDATA[U. S ]]></publisher-loc>
<publisher-name><![CDATA[National Library of Medicine, Clinical-Trials.gov]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
